Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. ACN
4. NAVN
5. DFTX
6. IBM
7. META
8. MU
9. DPZ
10. MSFT

Go back to Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
(NASDAQ: ADAG) Delayed: 3.84 --0 (-0%)
Previous Close $3.84    52 Week High $ 
Open $3.84    52 Week Low $ 
Day High $3.84    P/E N/A 
Day Low $3.84    EPS $ 
Volume 500       

(NASDAQ: ADAG) Delayed: 3.84 --0 (-0%)
Previous Close $3.84    52 Week High $ 
Open $3.84    52 Week Low $ 
Day High $3.84    P/E N/A 
Day Low $3.84    EPS $ 
Volume 500       

Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 103.66 --0 (-0%)
Previous Close $103.66    52 Week High $118.49 
Open $103.66    52 Week Low $55.00 
Day High $103.66    P/E N/A 
Day Low $103.66    EPS $-0.56 
Volume 1,143